Venetoclax (Ven), an oral agent that targets the antiapoptotic protein, BCL-2, has demonstrated efficacy, as monotherapy and combined with proteasome inhibitor (PI) bortezomib, in relapsed/refractory (R/R) multiple myeloma (MM). We report preliminary safety and efficacy data for Ven combined with the second generation PI carfilzomib (K) and dexamethasone (VenKd) in R/R MM.

The combination of VenKd appears tolerable with no new safety signals or changes in Ven pharmacokinetics. VenKd shows promising preliminary efficacy in R/R MM patient subgroups. Response rates were comparable in all high risk subgroups and overall population. However, the subset of patients with t(11;14) had the highest response.

Overall, these results demonstrate that VenKd is a safe and efficacious regimen in R/R MM and support the continued study of VenKd. 303 Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma


Luciano Costa, M.D., is an Associate Professor of Medicine Blood and Marrow Transplantation and Cell Therapy Program at the University of Alabama in Birmingham, Alabama. His main areas of focus include strategies for hematopoietic stem cell transplantation in chronic lymphoproliferative disorders, the toxicity of hematopoietic stem cell transplantation, and population outcomes of hematologic malignancies. View Dr. Luciano Costa’s full biography here.

Previous Post
Seeking AL Amyloidosis Very Early: The SAVE Trial
Next Post
Bispecific T-cell Engagers (BiTEs)

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.